Alzheimer’s Early Detection Act of 2026
- Sponsor
- Rep. Auchincloss, Jake [D-MA-4]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 22, 2026
Bottom line
The bill aims to expand access to early detection and management tools for Alzheimer's disease by requiring broad insurance coverage for biomarker testing across both private and public health programs.
What it actually does
This bill mandates that private health insurance plans and state Medicaid programs provide coverage for Alzheimer's biomarker testing. It establishes specific requirements for how this coverage must be offered, including limits on cost-sharing, prior authorization timelines, and a prohibition on step therapy, while also broadly defining what constitutes Alzheimer's biomarker testing. Additionally, it requires the National Institutes of Health to conduct studies on the value of such testing.
Proponents argue
Supporters argue that early detection of Alzheimer's through biomarker testing is crucial for timely intervention, better disease management, and improved patient outcomes. They contend that mandated coverage will reduce financial barriers, promote equitable access, and align with advancements in medical science, potentially slowing disease progression and improving quality of life for affected individuals and their families.
Opponents contend
Potential opponents might raise concerns about the increased costs to health plans, insurers, and state Medicaid programs, which could lead to higher premiums or strain state budgets. They might also question the clinical utility and cost-effectiveness of widespread biomarker testing for all populations, especially given the current limitations in disease-modifying treatments for Alzheimer's.
The bill is short and relatively straightforward, allowing for a quick and informed review by an interested reader.
Section 2(a)(1), new Section 2730(a) of the Public Health Service Act.
Required Coverage of Alzheimer's Biomarker Testing by Private Insurers
This provision mandates that all group health plans and health insurance issuers offering group or individual coverage must provide benefits for Alzheimer's biomarker testing. This means private insurance companies are federally required to cover these diagnostic tests for their enrollees, removing a potential financial barrier to access.
Supporters argue
Supporters argue this mandate ensures that individuals at risk or showing symptoms of Alzheimer's can access critical diagnostic tools without prohibitive out-of-pocket costs, leading to earlier diagnosis and potentially better disease management.
Critics contend
Critics may argue that such mandates increase healthcare costs, which could be passed on to consumers through higher premiums, and may limit the flexibility of health plans to design benefits based on their specific populations' needs and cost-effectiveness analyses.
Tradeoffs
This provision balances the goal of expanding access to advanced diagnostic testing against concerns about rising healthcare costs and potential impacts on insurance premiums.
Section 2(a)(1), new Section 2730(b) of the Public Health Service Act.
Rules for How Private Insurance Must Cover Biomarker Testing
This section specifies that private insurance coverage for Alzheimer's biomarker testing must be equitable and accessible. It prohibits more restrictive financial requirements (e.g., higher co-pays) or treatment limitations compared to other medical benefits. It also sets strict prior authorization timelines (72 hours, or 24 hours for urgent cases), bans step therapy, and requires coverage to promote equitable access, including for rural and underserved populations, and support minimally invasive testing.
Section 2(a)(1), new Section 2730(c) of the Public Health Service Act.
Comprehensive Definition of Covered Alzheimer's Biomarker Testing
This provision broadly defines 'Alzheimer's biomarker testing' to include the analysis of tissue, blood, or other biospecimens for biomarkers, encompassing various technologies like single-analyte tests, multiplex panels, protein expression, and advanced genetic sequencing (whole genome, whole exome, and whole transcriptome sequencing). It specifies that testing must be for purposes such as early detection, diagnosis, treatment management, or monitoring of Alzheimer's disease, and must align with FDA indications, Medicare coverage, or applicable clinical guidelines.
Section 2(b) of the bill, amending Section 1905(a) and 1902(a) of the Social Security Act.
Mandatory Medicaid Coverage for Alzheimer's Biomarker Testing
This provision amends the Social Security Act to include Alzheimer's biomarker testing as a mandatory covered medical assistance service under the Medicaid program. It also requires state Medicaid programs to cover these tests in the same manner as private insurance, adhering to the same rules regarding financial requirements, treatment limitations, prior authorization, and step therapy.
Section 2(c).
Study and Report on the Value of Alzheimer's Biomarker Testing
This section directs the Director of the National Institutes of Health (NIH), through a contract with the National Academies of Sciences, Engineering, and Medicine, to conduct a study and submit annual reports to Congress for three years. The reports will assess the value of biomarker testing in detecting and treating Alzheimer's disease.
The definition of 'Alzheimer's biomarker testing' explicitly includes advanced genetic sequencing technologies such as 'whole genome, whole exome, and whole transcriptome sequencing.'
Section 2(a)(1), new Section 2730(c)(1) of the Public Health Service Act.
Why it matters:This level of detail is standard for definitions in legislative text to ensure comprehensive and future-proof coverage. It might also be included to preemptively address potential insurer arguments against covering these specific advanced tests.
Case for: Proponents would argue that including these advanced sequencing technologies is crucial for comprehensive and cutting-edge Alzheimer's diagnosis and management, especially as the understanding of genetic predispositions and personalized medicine for Alzheimer's evolves. It ensures the bill remains relevant with scientific progress.
Case against: Critics might argue that mandating coverage for such expensive and complex tests, particularly whole genome sequencing, without clear, immediate clinical actionability for all individuals, could significantly increase healthcare costs without proportional patient benefit in the short term.
Estimated impact: Potentially significant cost implications for insurers and Medicaid programs, as these tests can be very expensive, and their widespread application could lead to substantial expenditures.